

1 Celgene

Acquired by: **Bristol-Myers Squibb (BMS)**
Price: **Approximately \$74 billion**

Deal status: BMS said June 24 that it expects to complete the purchase “at the end of 2019 or the beginning of 2020,” rather than during Q3 as predicted when the deal was announced on January 3. BMS also agreed to sell off the psoriasis drug Otezla® (apremilast) to address U.S. Federal Trade Commission concerns. Shareholders of both companies have approved the blockbuster deal, designed to create a powerhouse in immunology and inflammation, cardiovascular disease, and oncology.

2 Allergan

Acquired by: **AbbVie**
Price: **\$63 billion**

Deal status: Announced June 25, the acquisition would create a \$48 billion biopharma giant, based on 2019 revenues, by strengthening AbbVie’s topline with the up-to-\$15.425 billion projected this year by Allergan. The deal, set to close in “early 2020,” comes as AbbVie is three years away from losing U.S. market exclusivity for its longtime top-selling drug Humira® (adalimumab), which topped GEN’s A-List of the Top 15 Best-Selling Drugs of 2018.

3 Shire

Acquired by: **Takeda Pharmaceutical**
Price: **£46 billion (\$58.6 billion)**

Deal status: Completed January 7. Takeda president and CEO Christophe Weber trumpeted the deal as accelerating “our transformation journey to deliver highly innovative medicines to patients around the world.” On January 28, Tokyo-based Takeda announced it was selling its former headquarters site in Osaka among non-core assets, in order to reduce debt that ballooned to ¥5.4 trillion (\$50.3 billion). In May, Weber ratcheted up projected annual savings to \$2 billion by the end of 2021, up from \$1.4 billion.

4 GE BioPharma (BioPharma business of GE Life Sciences)

Acquired by: **Danaher**
Price: **Approximately \$21.4 billion**

Deal status: Announced February 25, the deal is designed to enhance Danaher’s bioprocessing offerings and pay down GE’s debt. Danaher president and CEO Thomas P. Joyce, Jr., said in the company’s first-quarter earnings press release on April 18 that his company continues to expect the deal to close in the fourth quarter of this year.

5 Array BioPharma

Acquired by: **Pfizer**
Price: **Approximately \$11.4 billion**

Deal status: Announced June 17, the planned acquisition reflects Pfizer’s intent to expand its oncology presence and pipeline. Array’s combination of Braftovi® (encorafenib) and Mektovi® (binimetinib) is approved for BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma, and is under study in 30+ clinical trials, including the Phase III BEACON trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer. The boards of Pfizer and Array have approved the acquisition, expected to be completed in 2H 2019.

6 Loxo Oncology

Acquired by: **Eli Lilly**
Price: **Approximately \$8 billion**

Deal status: Completed February 15. Eli Lilly jolted this year’s J.P. Morgan 37th Healthcare Conference in San Francisco when it announced the deal January 7. Lilly signaled it was serious about catching up in cancer drug development by becoming a top-tier precision oncology company, Brad Loncar, CEO of Loncar Investments, who tracks developments in cancer immunotherapy and the broader biopharma industry, told GEN.

7 Tesaro

Acquired by: **GlaxoSmithKline (GSK)**
Price: **Approximately \$5.1 billion**

Deal status: Completed January 22. GSK said the acquisition, announced December 3, 2018, was intended to “significantly” accelerate the development of its pipeline and commercial capability in oncology with Tesaro’s marketed once-daily oral poly ADP ribose polymerase (PARP) inhibitor Zejula™ (niraparib), under study for several additional cancer indications. GSK also cited Tesaro’s pipeline of additional oncology candidates, including antibodies directed against PD-1, TIM-3, and LAG-3 targets.

8 Spark Therapeutics

Acquired by: **Roche**
Price: **\$4.8 billion**

Deal status: On June 10, Roche extended again its tender offer for Spark shares, after both companies received a request from the U.S. Federal Trade Commission for additional information tied to its review of the acquisition, announced February 25. Spark shareholders now have until July 31 to tender their shares. On June 7, approximately 21.1% of Spark’s outstanding shares had been validly tendered. At least 50% of Spark shares are required to complete the deal.

9 Peloton Therapeutics

Acquired by: **Merck & Co.**
Price: **Up to \$2.2 billion**

Deal status: Expected to close in the third quarter. Merck aims to expand its cancer pipeline through the deal, announced May 21. Merck plans through a subsidiary to acquire all outstanding shares of Peloton in exchange for \$1.05 billion cash upfront. Merck has also agreed to pay Peloton shareholders up to \$1.15 billion tied to achieving regulatory and sales milestones.

10 Thermo Fisher Scientific

Acquired by: **Brammer Bio**
Price: **Approximately \$1.7 billion**

Deal status: Completed May 1. Thermo Fisher Scientific increased its presence in gene therapy with the viral vector contract development and manufacturing organization through the deal, announced March 24. Brammer’s chief operations officer before the deal—Christopher K. Murphy, now vp and general manager of viral vector services in Thermo Fisher’s Pharma Services Group—told GEN in June that Thermo Fisher will complete \$100 million in Brammer Bio capital expansion projects designed to satisfy growing demand for gene therapies for clinical and commercial use.

See more lists online
GENengnews.com/lists